4basebio (LON:4BB) Shares Down 0.2% – Here’s Why

Shares of 4basebio PLC (LON:4BB) dropped 0.2% during mid-day trading on Friday . The company traded as low as GBX 501 and last traded at GBX 524. Approximately 13 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 1,729 shares. The stock had previously closed at GBX 525.

4basebio Stock Down 0.2%

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The stock’s 50-day simple moving average is GBX 501.26 and its 200-day simple moving average is GBX 556.46. The firm has a market capitalization of £81.14 million, a P/E ratio of -4.81 and a beta of 1.09.

4basebio (LON:4BB) last issued its quarterly earnings data on Wednesday, May 20th. The company reported GBX (1.09) earnings per share (EPS) for the quarter. The business had revenue of GBX 169 million for the quarter. As a group, research analysts predict that 4basebio PLC will post -3.43 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Amy Walker purchased 1,863 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of GBX 509 per share, for a total transaction of £9,482.67. 12.09% of the stock is currently owned by insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.